S3 Ep24: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact - a podcast by Not So Different: a Podcast from The Center for Biosimilars

As summer fades away and the United States prepares for a potential second wave of coronavirus disease 2019 (COVID-19) cases, many are worried that economic impacts and rising health care costs will continue unless action is taken. Europe’s competitive biosimilar market has proven that biosimilars have the potential to lower costs. But with existing barriers, such as lack of education and payer oversight of formularies, and the continuing pandemic, there is some debate on whether biosimilars will have the same impact in the United States.
We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss how biosimilars can help curb costs in the time of COVID-19 and beyond.

Further episodes of Not So Different: a Podcast from The Center for Biosimilars

Further podcasts by Not So Different: a Podcast from The Center for Biosimilars

Website of Not So Different: a Podcast from The Center for Biosimilars